Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 30;11:576603. doi: 10.3389/fimmu.2020.576603

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Wang, Ding, Liu, Zhang, Xu, Xia, Duan, Wang, Ji, Huang, Zhao, Cao, Shen and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Determination of the Immunoreactivity to WT and MT peptides in HLA-A2⁺ BC patients. (A) Representatives of peptide-specific IFN-γ releases by an ELISPOT assay. PBMCs from Patient 25 were isolated and stimulated with 12 WT and MT peptides individually in vitro for 20 h. RPMI 1640 medium was used as BLANK while PHA as a positive control. The number of the spot-forming units (SFUs) of each well was shown as well. (B) The SFUs specific to 12 WT and MT peptides in Patient 25. (C) The average SFUs of 12 WT and MT peptides in 40 HLA-A2⁺ BC patients (the average SFUs = total SFUs from the tested peptides/the number of tested peptides). (D) Comparison of average SFUs between WT and MT peptides by the paired Student t test. Each line represented one patient.